Intensification lessons with modern premixes: from clinical trial to clinical practice - PubMed (original) (raw)
Review
. 2008 Sep:81 Suppl 1:S23-30.
doi: 10.1016/j.diabres.2008.06.010. Epub 2008 Aug 5.
Affiliations
- PMID: 18684540
- DOI: 10.1016/j.diabres.2008.06.010
Review
Intensification lessons with modern premixes: from clinical trial to clinical practice
Serdar Guler et al. Diabetes Res Clin Pract. 2008 Sep.
Abstract
This paper aims to underscore the importance of insulin intensification, while highlighting the clinical utility of modern premixes through intensification lessons, by utilising data from key clinical trials, and from the recently published large observational PRESENT Study. Insulin intensification is any change made to an initial insulin regimen to improve glycaemic control. Yet, despite established glycaemic targets, current HbA1c levels in insulin-treated patients suggest that 'real-world' insulin regimens are not optimally intensified. When treatment is intensified as needed, patients are more likely to achieve and maintain glycaemic targets, as evidenced by treat-to-target trials utilising forced titration algorithms. Both clinical and observational studies suggest that modern premixes, such as biphasic insulin aspart 30, represent an effective and well-tolerated option when intensifying a number of existing insulin regimens that no longer maintain optimal glycaemic control. However, physician and patient concerns regarding initiation and intensification of insulin therapy can create barriers to effective patient care, and it is essential that such barriers be resolved. Although it is important to encourage patients to initiate insulin therapy when needed, it is equally important that insulin regimens benefit from ongoing intensification in order to maintain glycaemic control as type 2 diabetes follows its typically progressive course.
Similar articles
- Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
Ligthelm RJ. Ligthelm RJ. Prim Care Diabetes. 2009 May;3(2):97-102. doi: 10.1016/j.pcd.2009.01.003. Epub 2009 Mar 13. Prim Care Diabetes. 2009. PMID: 19285933 - Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial.
van Dieren S, Kengne AP, Chalmers J, Beulens JW, Davis TM, Fulcher G, Heller SR, Patel A, Colagiuri S, Hamet P, Mancia G, Marre M, Neal B, Williams B, Peelen LM, van der Schouw YT, Woodward M, Zoungas S. van Dieren S, et al. Diabetes Obes Metab. 2014 May;16(5):426-32. doi: 10.1111/dom.12238. Epub 2013 Dec 16. Diabetes Obes Metab. 2014. PMID: 24251579 Clinical Trial. - Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Halimi S, et al. Clin Ther. 2005;27 Suppl B:S57-74. doi: 10.1016/j.clinthera.2005.11.021. Clin Ther. 2005. PMID: 16519038 Review. - Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?".
Ghosal S, Sinha B, Majumder A, Das AK, Singh AK, Ghoshdastidar B, Maji D, Goyal G, Mukherjee JJ, Gangopadhyay KK, John M, Chatterjee S, Jaggi S, Ray S, Majumdar S, Sharma SK. Ghosal S, et al. J Assoc Physicians India. 2017 Jul;65(7):51-62. J Assoc Physicians India. 2017. PMID: 28792170 - Insulin initiation and intensification: insights from new studies.
Kumar A, Kalra S. Kumar A, et al. J Assoc Physicians India. 2011 Apr;59 Suppl:17-22. J Assoc Physicians India. 2011. PMID: 21818994
Cited by
- Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
Suzuki K, Mitsuma Y, Sato T, Anraku T, Hatta M. Suzuki K, et al. J Clin Med Res. 2016 Nov;8(11):805-814. doi: 10.14740/jocmr2741w. Epub 2016 Sep 29. J Clin Med Res. 2016. PMID: 27738482 Free PMC article. - Do We Need Updated Guidelines on the Use of Insulin Pump Therapy in Type 2 Diabetes? A Review of National and International Practice Guidelines.
Cohen O, Valentine W. Cohen O, et al. J Diabetes Sci Technol. 2016 Nov 1;10(6):1388-1398. doi: 10.1177/1932296816667747. Print 2016 Nov. J Diabetes Sci Technol. 2016. PMID: 27621141 Free PMC article. Review. - Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
Chen C, Yu Q, Zhang S, Yang P, Wang CY. Chen C, et al. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14141-50. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26823727 Free PMC article. Review. - Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc).
Polinski JM, Kim SC, Jiang D, Hassoun A, Shrank WH, Cos X, Rodríguez-Vigil E, Suzuki S, Matsuba I, Seeger JD, Eddings W, Brill G, Curtis BH. Polinski JM, et al. BMC Endocr Disord. 2015 Sep 9;15:46. doi: 10.1186/s12902-015-0044-z. BMC Endocr Disord. 2015. PMID: 26353820 Free PMC article. - Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM trial investigators. Rosenstock J, et al. Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503. Epub 2015 Jul 14. Diabetes Obes Metab. 2015. PMID: 26040302 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical